Copyright: ©Author(s) 2026.
World J Clin Oncol. Oct 24, 2026; 17(10): 124301
Published online Oct 24, 2026. doi: 10.5306/wjco.124301
Published online Oct 24, 2026. doi: 10.5306/wjco.124301
Table 2 Baseline characteristics before and after inverse probability weighting, n (%)/mean ± SD
| Covariate | Treatment (n = 490) | Control (n = 137) | P value | Treatment (n = 259) | Control (n = 111) | P value |
| Age | - | - | 0.844 | - | - | 0.905 |
| < 60 years | 291 (59.39) | 83 (60.58) | - | 107 (41.31) | 44 (39.64) | - |
| ≥ 60 years | 199 (40.61) | 54 (39.42) | - | 152 (58.69) | 67 (60.36) | - |
| Sex | - | - | 0.493 | - | - | 0.264 |
| Male | 201 (41.02) | 61 (44.52) | - | 156(60.23) | 56 (50.45) | - |
| Female | 289 (59.98) | 76 (55.48) | - | 103 (39.77) | 55 (49.55) | - |
| Tumor location | - | - | 0.105 | - | - | 0.305 |
| Left colon | 347 (70.82) | 107 (78.10) | - | 190 (73.36) | 95 (85.59) | - |
| Right colon | 143 (29.18) | 30 (21.90) | - | 69 (26.64) | 16 (14.41) | - |
| Histology | - | - | 0.019 | - | - | 0.140 |
| Adenocarcinoma | 451 (92.04) | 117 (85.40) | - | 238 (91.89) | 92 (82.88) | - |
| Non-adenocarcinoma | 39 (7.96) | 20 (14.60) | - | 21 (8.11) | 19 (17.12) | - |
| Gene type | - | - | 0.752 | - | - | 0.375 |
| Wild type | 146 (29.80) | 43 (31.39) | - | 83 (32.05) | 46 (41.44) | - |
| Mutant | 344 (70.20) | 94 (68.62) | - | 176 (67.95) | 65 (58.56) | - |
| Prior treatment | - | - | 0.528 | - | - | 0.898 |
| Treatment-naïve | 167 (34.08) | 35 (25.55) | - | 84 (32.43) | 33 (29.73) | - |
| First- or second-line | 265 (54.08) | 78 (56.93) | - | 138 (53.28) | 66 (59.46) | - |
| Third-line or later | 58 (11.84) | 24 (17.52) | - | 37 (14.29) | 12 (10.81) | - |
| Palliative surgery | 272 (55.51) | 75 (54.74) | 0.923 | 147 (56.76) | 58 (52.25) | 0.575 |
| Prior targeted therapy | 186 (37.96) | 44 (32.12) | 0.230 | 92 (35.52) | 28 (25.23) | 0.272 |
| Comorbidities | 148 (30.20) | 75 (54.74) | < 0.001 | 90 (34.75) | 54 (48.65) | 0.155 |
| TCM deficiency syndromes | - | - | 0.187 | - | - | 0.755 |
| Spleen-kidney deficiency | 175 (35.72) | 77 (56.20) | - | 95 (36.68) | 47 (42.35) | - |
| Liver-kidney deficiency | 76 (15.51) | 23 (16.79) | - | 44 (16.99) | 18 (16.22) | - |
| Liver qi stagnation with spleen deficiency | 141 (28.78) | 12 (8.76) | - | 65 (25.10) | 25 (22.52) | - |
| Lung-kidney deficiency | 43 (8.76) | 13 (9.49) | - | 24 (9.27) | 8 (7.20) | - |
| Lung–spleen deficiency | 26 (5.31) | 9 (6.57) | - | 16 (6.18) | 8 (7.20) | - |
| Others | 29 (5.92) | 3 (2.19) | - | 15 (5.79) | 5 (4.51) | - |
| TCM excess syndromes | - | - | 0.001 | - | - | 0.687 |
| Phlegm-stasis obstruction | 236 (48.16) | 60 (43.79) | - | 144 (55.60) | 53 (47.75) | - |
| Stasis-toxin obstruction | 75 (15.31) | 11 (8.03) | - | 31 (11.97) | 17 (15.32) | - |
| Phlegm-damp retention | 156 (31.84) | 48 (35.04) | - | 80 (30.89) | 33 (29.73) | - |
| Internal retention of dampness | 23 (4.69) | 18 (13.14) | - | 4 (1.54) | 9 (7.20) | - |
| KPS | - | - | < 0.001 | - | - | 0.372 |
| < 80 | 295 (60.20) | 40 (29.20) | 139 (53.67) | 67 (60.36) | - | |
| ≥ 80 | 195 (39.80) | 97 (70.80) | 120 (46.33) | 44 (39.64) | - | |
| BMI | 23.49 ± 3.91 | 23.65 ± 3.64 | 0.769 | 23.58 ± 3.90 | 22.96 ± 3.75 | 0.427 |
| Metastatic sites | ||||||
| Liver | 287 (58.57) | 84 (61.31) | 0.694 | 147 (56.76) | 67 (60.36) | 0.383 |
| Lung | 182 (37.14) | 56 (40.88) | 0.488 | 106 (40.93) | 46 (41.44) | 0.947 |
| Brain | 15 (3.06) | 7 (5.11) | 0.296 | 10 (3.86) | 3 (2.70) | 0.409 |
| Peritoneum | 34 (6.93) | 10 (7.30) | 0.852 | 12 (4.63) | 9 (8.11) | 0.734 |
- Citation: Li R, Xu YY, Wu BB, Wang MM, Guan L, Li BR, Wang YW, Yang YF, Pang B. Clinical efficacy of integrated Chinese-Western medicine therapy for metastatic colorectal cancer. World J Clin Oncol 2026; 17(10): 124301
- URL: https://www.wjgnet.com/2218-4333/full/v17/i10/124301.htm
- DOI: https://dx.doi.org/10.5306/wjco.124301